NCT06295211View on ClinicalTrials.gov

Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

September 1, 2023

Study Completion Date

February 22, 2024

Conditions
Hodgkin Lymphoma
Interventions
OTHER

observational

observational

All Listed Sponsors
lead

Federico II University

OTHER

NCT06295211 - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study. | Biotech Hunter | Biotech Hunter